AstraZeneca : Tagrisso plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline
Kort samengevat
Results from a prespecified exploratory analysis of the FLAURA2 Phase III trial showed AstraZeneca
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij MarketScreener.
Lees het volledige bericht ↗